According to Meridian Bioscience's latest financial reports the company has a price-to-book ratio of 4.05.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Year | P/B ratio | Change |
---|---|---|
2022-12-31 | 3.95 | 53.8% |
2021-12-31 | 2.57 | -11.04% |
2020-12-31 | 2.89 | 36.28% |
2019-12-31 | 2.12 | -48.63% |
2018-12-31 | 4.13 | 20.51% |
2017-12-31 | 3.43 | -23.98% |
2016-12-31 | 4.51 | -11.93% |
2015-12-31 | 5.12 | 19.93% |
2014-12-31 | 4.27 | -39.07% |
2013-12-31 | 7.00 | 15.5% |
2012-12-31 | 6.06 | 7.46% |
2011-12-31 | 5.64 | -18.78% |
2010-12-31 | 6.95 | 11.51% |
2009-12-31 | 6.23 | -20.26% |
2008-12-31 | 7.81 | -24.11% |
2007-12-31 | 10.3 | 57.5% |
2006-12-31 | 6.54 | 8.44% |
2005-12-31 | 6.03 | -16.4% |
2004-12-31 | 7.21 | 35.13% |
2003-12-31 | 5.34 | 32% |
2002-12-31 | 4.04 |
Company | P/B ratio | differencediff. | Country |
---|---|---|---|
Thermo Fisher Scientific TMO | 4.41 | 9.09% | ๐บ๐ธ USA |
Becton Dickinson BDX | 2.66 | -34.27% | ๐บ๐ธ USA |
Hologic HOLX | 3.79 | -6.36% | ๐บ๐ธ USA |
QuidelOrtho QDEL | 0.5112 | -87.36% | ๐บ๐ธ USA |